SARS-CoV-2 Neutralizing Antibodies Post Second-dose Vaccination in Santo Domingo, Ecuador
Keywords:
COVID-19 vaccines, antibody titer, SARS-CoV-2, immunization schedules.Abstract
Introduction: Studies of neutralizing antibody levels could help to know the immune protection generated against SARS-CoV-2 virus, for which it is necessary to examine these levels with in vitro assays after vaccination.
Objective: To evaluate the generation of neutralizing anti-SARS-CoV-2 antibodies according to gender, age and vaccination schedule in the population vaccinated with second dose in Santo Domingo, Ecuador.
Methods: An observational, descriptive and retrospective cross-sectional study of the results of neutralizing antibodies against SARS-CoV-2 was carried out. The population and sample consisted of 83 individuals who attended the Campos Clinical Laboratory in the city of Santo Domingo, Ecuador, between May and November 2021, with a complete primary vaccination schedule (1st and 2nd doses) against COVID-19. Data processing was performed with the Statistical Package for Social Sciences (SPSS) version 25.
Results: Of the 83 individuals who attended the Campos Clinical Laboratory for the determination of anti-SARS-CoV-2 neutralizing antibodies, 70 received two doses of the same vaccine, 10 received a heterologous vaccination schedule (1st dose Pfizer-BioNTech, 2nd dose SinoVac/CoronaVac), two received two doses of ChAdOx1-S (recombinant) from Oxford/AstraZeneca and one received a single dose of Cansino/Convidecia. The average age was 36.5 years and 61% of the total individuals were female. In 97% of the individuals the neutralizing antibody concentration was greater than or equal to 0.03µg/mL.
Conclusions: In the study sample, no significant differences were found in antibody concentrations according to the vaccination scheme received, although significant differences were appreciated with respect to sex and age, there were higher neutralizing antibody titers in the female sex and in individuals 50 years of age or older, the latter presented a higher concentration of neutralizing anti-SARS-CoV-2 antibodies, in the three vaccination schemes analyzed.
